NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis $3.45 +0.59 (+20.63%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.94▼$3.5050-Day Range$1.17▼$3.8552-Week Range$0.89▼$4.52Volume1.87 million shsAverage Volume1.94 million shsMarket Capitalization$179.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Personalis alerts: Email Address Personalis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.9% Upside$5.00 Price TargetShort InterestHealthy3.50% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.94Based on 4 Articles This WeekInsider TradingSelling Shares$11,722 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.26) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.50 out of 5 starsMedical Sector107th out of 936 stocksMedical Laboratories Industry6th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 2 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.50% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently increased by 6.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePersonalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Personalis is -0.66. Previous Next 3.9 News and Social Media Coverage News SentimentPersonalis has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Personalis this week, compared to 1 article on an average week.Search Interest10 people have searched for PSNL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Personalis to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,722.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.26) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Personalis Stock (NASDAQ:PSNL)Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More PSNL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSNL Stock News HeadlinesJuly 25 at 3:59 PM | finance.yahoo.comPersonalis to Announce Second Quarter 2024 Financial ResultsJuly 20, 2024 | finance.yahoo.comEven after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three yearsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 18, 2024 | businesswire.comPersonalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution ConferenceJune 13, 2024 | businesswire.comPersonalis Provides Dial-in and Updated Date for ASCO Highlights Conference CallMay 31, 2024 | businesswire.comPersonalis Announces Start of Cancer MRD Testing Commercialization Collaboration with TempusMay 22, 2024 | finance.yahoo.comPersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024May 22, 2024 | businesswire.comPersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 17, 2024 | businesswire.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amid Strong Financial Performance and Strategic Growth ProspectsMay 9, 2024 | markets.businessinsider.com4 Analysts Have This To Say About PersonalisMay 9, 2024 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comPersonalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comIs Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?May 9, 2024 | finance.yahoo.comPersonalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...May 8, 2024 | investorplace.comPSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comPersonalis Reports First Quarter 2024 Financial ResultsSee More Headlines Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:PSNL CUSIPN/A CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$7.50 Low Stock Price Target$3.50 Potential Upside/Downside+44.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-124.89% Pretax Margin-124.79% Return on Equity-58.31% Return on Assets-37.57% Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick Ratio3.56 Sales & Book Value Annual Sales$73.48 million Price / Sales2.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book1.31Miscellaneous Outstanding Shares51,940,000Free Float49,810,000Market Cap$179.19 million OptionableOptionable Beta1.86 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Christopher M. Hall (Age 55)President, CEO & Director Comp: $963.75kMr. Aaron L. Tachibana (Age 63)CFO & COO Comp: $811kMr. Stephen M. Moore J.D. (Age 52)Senior VP & Chief Legal Officer Comp: $597.98kDr. Richard Chen M.D. (Age 53)M.S., Executive VP of R&D and Chief Medical Officer Comp: $800.6kDr. Russ B. Altman M.D.Ph.D., Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Euan A. Ashley DPHIL (Age 53)FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Michael P. Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Michael J FitzpatrickVice President of Worldwide SalesDr. Christian Haudenschild Ph.D.Senior Vice President of Genomic Laboratory OperationsMr. Stephane Mouradian Ph.D.Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsMacroGenicsNASDAQ:MGNXCastle BiosciencesNASDAQ:CSTLGrailNASDAQ:GRALDocGoNASDAQ:DCGOLifeMDNASDAQ:LFMDView All CompetitorsInsiders & InstitutionsARK Investment Management LLCBought 296,413 shares on 7/26/2024Ownership: 12.249%Sumitomo Mitsui Trust Holdings Inc.Sold 92,217 shares on 7/19/2024Ownership: 1.705%Virtu Financial LLCBought 27,664 shares on 5/20/2024Ownership: 0.053%Aaron TachibanaSold 1,333 sharesTotal: $1,839.54 ($1.38/share)Richard ChenSold 940 sharesTotal: $1,297.20 ($1.38/share)View All Insider TransactionsView All Institutional Transactions PSNL Stock Analysis - Frequently Asked Questions How have PSNL shares performed this year? Personalis' stock was trading at $2.10 at the beginning of 2024. Since then, PSNL shares have increased by 64.3% and is now trading at $3.45. View the best growth stocks for 2024 here. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) announced its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.18. The business had revenue of $19.53 million for the quarter, compared to analyst estimates of $18.49 million. Personalis had a negative trailing twelve-month return on equity of 58.31% and a negative net margin of 124.89%. What is John West's approval rating as Personalis' CEO? 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees. When did Personalis IPO? Personalis (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Top institutional investors of Personalis include ARK Investment Management LLC (12.25%) and Sumitomo Mitsui Trust Holdings Inc. (1.70%). Insiders that own company stock include John Stephen West, Christopher M Hall, Aaron Tachibana, Richard Chen, Stephen Michael Moore and Lightspeed Venture Partners Se. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO) and NVIDIA (NVDA). This page (NASDAQ:PSNL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.